The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways
Open accessAbstract
Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies. However, after prolonged fulvestrant therapy, acquired resistance eventually occurs in the majority of breast cancer patients, due to poorly understood mechanisms. To examine a possible role(s) of aberrantly expressed microRNAs (miRNAs) in acquired fulvestrant resistance, we compared antiestrogen-resistant and -sensitive breast cancer cells, revealing the overexpression of miR-221/222 in the SERD-resistant cell lines. Fulvestrant treatment of estradiol (E2)- and fulvestrant-sensitive MCF7 cells resulted in increased expression of endogenous miR-221/222. Ectopic upregulation of miR-221/222 in estrogen receptor-α (ERα)-positive cell lines counteracted the effects of E2 depletion or fulvestrant-induced cell death, thus also conferring hormone-independent growth and fulvestrant resistance. In cells with acquired resistance to fulvestrant, miR-221/222 expression was essential for cell growth and cell cycle progression. To identify possible miR-221/222 targets, miR-221- or miR-222- induced alterations in global gene expression profiles and target gene expression at distinct time points were determined, revealing that miR-221/222 overexpression resulted in deregulation of multiple oncogenic signaling pathways previously associated with drug resistance. Activation of β-catenin by miR-221/222 contributed to estrogen-independent growth and fulvestrant resistance, whereas TGF-β-mediated growth inhibition was repressed by the two miRNAs. This first in-depth investigation into the role of miR-221/222 in acquired fulvestrant resistance, a clinically important problem, demonstrates that these two ‘oncomirs’ may represent promising therapeutic targets for treating hormone-independent, SERD-resistant breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Garofalo, M., Di Leva, G., Romano, G., Nuovo, G., Suh, S.-S., Ngankeu, A., Taccioli, C., Pichiorri, F., Alder, H., Secchiero, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.014 · Cited by 733
Self-citationRetractedZhao, J.-J., Lin, J., Yang, H., Kong, W., He, L., Ma, X., Coppola, D., & Cheng, J. Q. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806041200 · Cited by 509
RetractedMaturation of MicroRNA Is Hormonally Regulated by a Nuclear Receptor
Yamagata, K., Fujiyama, S., Ito, S., Ueda, T., Murata, T., Naitou, M., Takeyama, K., Minami, Y., O’Malley, B. W., & Kato, S. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.011 · Cited by 71
RetractedKEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Self-citationPrediction of Mammalian MicroRNA Targets
Lewis, B. P., Shih, I.-H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003) · Cell · doi:10.1016/s0092-8674(03)01018-3 · Cited by 5,199
(2008) · doi:10.1038/nrg2290 · Cited by 5,199
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
Self-citationJohn, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020363 · Cited by 3,796
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Causes and consequences of microRNA dysregulation in cancer
Croce, C. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2634 · Cited by 2,998
Self-citationConstitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon Carcinoma
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., & Clevers, H. (1997) · Science · doi:10.1126/science.275.5307.1784 · Cited by 2,905
Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation
Vasudevan, S., Tong, Y., & Steitz, J. A. (2007) · Science · doi:10.1126/science.1149460 · Cited by 2,822
Bushati, N., & Cohen, S. M. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.23.090506.123406 · Cited by 2,750
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06174 · Cited by 2,605
The role of site accessibility in microRNA target recognition
Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., & Segal, E. (2007) · Nature Genetics · doi:10.1038/ng2135 · Cited by 2,460
Massagué, J. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043051 · Cited by 1,899
Garzon, R., Calin, G. A., & Croce, C. M. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.59.053006.104707 · Cited by 1,770
Self-citationAutophagy as a cell death and tumor suppressor mechanism
Gozuacik, D., & Kimchi, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207521 · Cited by 1,384
A systems biology approach for pathway level analysis
Draghici, S., Khatri, P., Tarca, A. L., Amin, K., Done, A., Voichita, C., Georgescu, C., & Romero, R. (2007) · Genome Research · doi:10.1101/gr.6202607 · Cited by 1,249
Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells
Shimono, Y., Zabala, M., Cho, R. W., Lobo, N., Dalerba, P., Qian, D., Diehn, M., Liu, H., Panula, S. P., Chiao, E., et al. (2009) · Cell · doi:10.1016/j.cell.2009.07.011 · Cited by 1,213
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Endocrine-responsive breast cancer and strategies for combating resistance
Ali, S., & Coombes, R. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc721 · Cited by 883
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Galardi, S., Mercatelli, N., Giorda, E., Massalini, S., Frajese, G. V., Ciafre, S. A., & Farace, M. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701805200 · Cited by 749
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., Jacob, S., & Majumder, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804612200 · Cited by 749
miR-221 overexpression contributes to liver tumorigenesis
Pineau, P., Volinia, S., McJunkin, K., Marchio, A., Battiston, C., Terris, B., Mazzaferro, V., Lowe, S. W., Croce, C. M., & Dejean, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907904107 · Cited by 699
Self-citationMiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma
Fornari, F., Gramantieri, L., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., Grazi, G. L., Giovannini, C., Croce, C. M., Bolondi, L., et al. (2008) · Oncogene · doi:10.1038/onc.2008.178 · Cited by 639
Self-citationDIANA-microT web server: elucidating microRNA functions through target prediction
Maragkakis, M., Reczko, M., Simossis, V. A., Alexiou, P., Papadopoulos, G. L., Dalamagas, T., Giannopoulos, G., Goumas, G., Koukis, E., Kourtis, K., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp292 · Cited by 562
A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation
Munafó, D. B., & Colombo, M. I. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.20.3619 · Cited by 516
Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?
Takahashi-Yanaga, F., & Kahn, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2943 · Cited by 499
Adams, B. D., Furneaux, H., & White, B. A. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0022 · Cited by 478
Visone, R., Russo, L., Pallante, P., De Martino, I., Ferraro, A., Leone, V., Borbone, E., Petrocca, F., Alder, H., Croce, C. M., et al. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0129 · Cited by 417
Self-citationUsing expression profiling data to identify human microRNA targets
Huang, J. C., Babak, T., Corson, T. W., Chua, G., Khan, S., Gallie, B. L., Hughes, T. R., Blencowe, B. J., Frey, B. J., & Morris, Q. D. (2007) · Nature Methods · doi:10.1038/nmeth1130 · Cited by 394
Foekens, J. A., Sieuwerts, A. M., Smid, M., Look, M. P., de Weerd, V., Boersma, A. W. M., Klijn, J. G. M., Wiemer, E. A. C., & Martens, J. W. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803304105 · Cited by 370
Estradiol-regulated microRNAs control estradiol response in breast cancer cells
Bhat-Nakshatri, P., Wang, G., Collins, N. R., Thomson, M. J., Geistlinger, T. R., Carroll, J. S., Brown, M., Hammond, S., Srour, E. F., Liu, Y., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp500 · Cited by 346
Gorsch, S. M., Memoli, V. A., Stukel, T. A., Gold, L. I., & Arrick, B. A. (1992) · PubMed · Cited by 343
The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response
Castellano, L., Giamas, G., Jacob, J., Coombes, R. C., Lucchesi, W., Thiruchelvam, P., Barton, G., Jiao, L. R., Wait, R., Waxman, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906947106 · Cited by 329
MicroRNA Cluster 221-222 and Estrogen Receptor α Interactions in Breast Cancer
Di Leva, G., Gasparini, P., Piovan, C., Ngankeu, A., Garofalo, M., Taccioli, C., Iorio, M. V., Li, M., Volinia, S., Alder, H., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq102 · Cited by 320
Self-citationmiR-206 Expression Is Down-regulated in Estrogen Receptor α–Positive Human Breast Cancer
Kondo, N., Toyama, T., Sugiura, H., Fujii, Y., & Yamashita, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0180 · Cited by 298
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F., & _, _. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00857 · Cited by 286
Regulation of p27Kip1by miRNA 221/222 in Glioblastoma
Gillies, J. K., & Lorimer, I. A. J. (2007) · Cell Cycle · doi:10.4161/cc.6.16.4526 · Cited by 259
Estrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E., Ariazi, J., Cordera, F., & Jordan, V. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776173483 · Cited by 255
Fan, M., Yan, P. S., Hartman-Frey, C., Chen, L., Paik, H., Oyer, S. L., Salisbury, J. D., Cheng, A. S. L., Li, L., Abbosh, P. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1666 · Cited by 248
Self-citationComparative Analyses of Mechanistic Differences Among Antiestrogens1
Wijayaratne, A. L., Nagel, S. C., Paige, L. A., Christensen, D. J., Norris, J. D., Fowlkes, D. M., & McDonnell, D. P. (1999) · Endocrinology · doi:10.1210/endo.140.12.7164 · Cited by 244
Estrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E. A., & Jordan, V. C. (2008) · Methods and Principles in Medicinal Chemistry · doi:10.1002/9783527623297.ch5 · Cited by 230
Li, M., Balch, C., Montgomery, J. S., Jeong, M., Chung, J. H., Yan, P., Huang, T. H., Kim, S., & Nephew, K. P. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-34 · Cited by 225
Self-citationKim, J., Zhang, X., Rieger-Christ, K. M., Summerhayes, I. C., Wazer, D. E., Paulson, K. E., & Yee, A. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513378200 · Cited by 203
The dark side of a tumor suppressor: anti-apoptotic p53
Jänicke, R. U., Sohn, D., & Schulze-Osthoff, K. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.33 · Cited by 187
Nam, S., Li, M., Choi, K., Balch, C., Kim, S., & Nephew, K. P. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp294 · Cited by 167
Self-citationIorio, M. V., Casalini, P., Tagliabue, E., Ménard, S., & Croce, C. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.037 · Cited by 158
Self-citationEstrogen Regulation of MicroRNA Expression
Klinge, C. (2009) · Current Genomics · doi:10.2174/138920209788185289 · Cited by 156
TGF‐Beta Signaling in Breast Cancer
Buck, M. B., & Knabbe, C. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1386.024 · Cited by 155
Kalkhoven, E., Roelen, B. A. J., de Winter, J. P., Mummery, C. L., Raaij, A. J. M. V. D. E.-V., van der Saag, P. T., & van der Burg, B. (1995) · PubMed · Cited by 155
MicroRNAs as Novel Biomarkers for Breast Cancer
Heneghan, H., Miller, N., Lowery, A., Sweeney, K. J., & Kerin, M. J. (2009) · Journal of Oncology · doi:10.1155/2010/950201 · Cited by 153
Invasion and metastasis of a mammary tumor involves TGF-? signaling
McEarchern, J. A., Kobie, J. J., Mack, V. E., Wu, R. S., Meade‐Tollin, L. C., Arteaga, C. L., Dumont, N., Besselsen, D. G., Seftor, E. A., Hendrix, M. J. C., et al. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20010101)91:1<76::aid-ijc1012>3.0.co;2-8 · Cited by 147
Endocrine therapy – current benefits and limitations
Nicholson, R. I., & Johnston, S. R. D. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9036-4 · Cited by 145
Zugmaier, G., Ennis, B. W., Deschauer, B., Katz, D. A., Knabbe, C., Wilding, G., Daly, P. F., Lippman, M. E., & Dickson, R. B. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041410217 · Cited by 133
Xin, F., Li, M., Balch, C., Thomson, M., Fan, M., Liu, Y., Hammond, S. M., Kim, S., & Nephew, K. P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn646 · Cited by 123
Self-citationPure oestrogen antagonists for the treatment of advanced breast cancer
Howell, A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.00846 · Cited by 118
Zhou, C., Nitschke, A., Xiong, W., Zhang, Q., Tang, Y., Bloch, M., Elliott, S. G., Zhu, Y., Bazzone, L. E., Yu, D. C., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2210 · Cited by 105
Self-citationWnt signaling inside the nucleus
Shitashige, M., Hirohashi, S., & Yamada, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00716.x · Cited by 95
Sovak, M. A., Arsura, M., Zanieski, G., Kavanagh, K. T., & Sonenshein, G. E. (1999) · PubMed · Cited by 87
Chen, Y., Banda, M., Speyer, C. L., Smith, J. S., Rabson, A. B., & Gorski, D. H. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01237-09 · Cited by 86
MicroRNA-221 and -222 pathway controls melanoma progression
Felicetti, F., Errico, M. C., Segnalini, P., Mattia, G., & Carè, A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.11.1759 · Cited by 70
Nicholson, R. I., Hutcheson, I. R., Hiscox, S., Knowlden, J. M., Giles, M., Barrow, D., & Gee, J. M. W. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00991 · Cited by 63
Resistance to Endocrine Therapy: Are Breast Cancer Stem Cells the Culprits?
O’Brien, C., Howell, S. J., Farnie, G., & Clarke, R. B. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9115-y · Cited by 62
Fulvestrant (‘Faslodex’): Current and future role in breast cancer management
Howell, A. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.001 · Cited by 54
Buck, M. B., Pfizenmaier, K., & Knabbe, C. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0278 · Cited by 47
Cited by
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
Self-citationIn vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Chen, Y., Gao, D.-Y., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.009 · Cited by 672
Trends in the development of miRNA bioinformatics tools
Chen, L., Heikkinen, L., Wang, C., Yang, Y., Sun, H., & Wong, G. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby054 · Cited by 603
RETRACTED AND REPLACED: microRNA involvement in human cancer
Iorio, M. V., & Croce, C. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs140 · Cited by 569
Self-citationRetractedPrognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
Metadata
- Authors
- Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., Burow, M. E., Ivan, M., Croce, C. M., & Nephew, K. P.
- Venue
- Oncogene
- Published
- 2010-11-08
- Volume
- 30
- Issue
- 9
- Pages
- 1082-1097
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2069588389
- Cited by
- 342
- References
- 71
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.